Eli Lilly’s experimental Alzheimer’s drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Administration.
More Stories
‘She has $18,000 in a 401(k)’: My live-in girlfriend, 62, refuses to save for retirement — and I’m unable to change her mind. What do you suggest?
‘Every time I mention it, she gets defensive and tells me it will work out.’
The stock market suffered a beatdown because investors suspect a Fed mistake
Investors fear, but don’t know for sure, if a long-awaited Federal Reserve rate cut has been left too long.
Apple’s iPhone 16 event is coming up Monday. What investors need to know.
Apple faces competing dynamics as it gears up to reveal the pricing of the new iPhone 16 models.
Decaying jobs market overtakes inflation as U.S. economy’s biggest threat
Lingering inflation was the chief threat to the U.S. economy just a few months ago. Now it’s a rapidly cooling...
Commercial real-estate investors are ready to get back in the market, says PGIM
Institutional capital is looking to “get off the sidelines and get back in,” said Soultana Reigle, head of U.S. equity...
Women just broke a job-market record. That may be a warning sign.
Friday’s jobs report showed a cooling labor market. But hiding in the data was one record-breaking stat about women in...